Kornimate/medical-research-clean huggingface dataset:
identifying functional and psycho-social complaints after hospitalization for sars-cov-2 infection( covid 19)- repercov

Conditions: SARS-COV2; COVID19

Summary: since december 2019, china and then the rest of the world have been affected by the rapid spread of a new coronavirus infection called sars-cov-2 (severe acute respiratory syndrome coronavirus), the clinical expression of which is called covid-19 (coronavirus disease 2019). it is estimated that around 20% of symptomatic patients will be severe enough to warrant hospitalization, of which around 5% will be in intensive care. organ damage is multiple in covid infection: respiratory, digestive, renal, neurological, cardiovascular due to the infection or its care. there is also a psychological and social impact of the infection or of the care that should be measured. in this context, investigator will assess the physical and psychological complaints of patients who have presented a severe form of sars-cov-2 infection. the final objective being to identify the needs to offer follow-up adapted to this emerging pathology.


Eligibility criteria:
inclusion criteria: * patient hospitalized for severe covid-19 infection between march 1 and june 30, 2020 in a conventional unit, intensive care unit, at the centre hospitalier du mans and alive at the time of the investigation at 2 to 3 months * patient having given their express consent, after having received the research information letter upon discharge from hospital or having given their express consent after sending the information letter * age ≥ 18 years * patient having contracted a sars-cov-2 infection proved by rt-pcr and / or retrospective serology and / or a covid-19 syndrome with suggestive chest scanner (during the period from march 1, 2020 to june 30, 2020) exclusion criteria: * patient opposition to participate in the cohort * non-french speaking patient * patients who cannot read or write * patient subject to a protective measure * patient not affiliated to a social security or equivalent health insurance

Keywords: sars-cov2 functionnal complaints sequel
systane hydration in subjects undergoing cataract surgery

Conditions: Dry Eye Disease; Cataract

Summary: the primary objective of this study is to demonstrate reduced corneal staining with use of systane hydration among subjects with dry eye disease (ded) undergoing routine cataract removal and monofocal intraocular lens (iol) implantation.

subjects will attend 6 scheduled study visits for an individual duration of participation of 6 weeks. one eye (study eye) will be followed.

Eligibility criteria:
key inclusion criteria: * seeking routine (age-related) cataract extraction with monofocal intraocular lens implantation; * able to provide informed consent; * willing and able to attend all study visits and comply with treatment; * have dry eyes per dry eye questionnaire. * other protocol-defined inclusion criteria may apply. key exclusion criteria: * subjects who use of ocular drugs, other than the test article (for treatment group only) and other standard of care postoperative medications, during the study; * history of intraocular or corneal surgery in the study eye; * use of artificial tears, steroids, or other medications as specified in the protocol; * clinically significant corneal scarring; * corneal degeneration, retinal degeneration or other ocular pathology as specified in the protocol. * other protocol-specified exclusion criteria may apply.
a clinical trial of the low dose chidamide in the management of refractory itp

Conditions: Thrombocytopenia

Summary: nowdays hdaci's were more and more focused on the anti-inflammatory and immunomodulatory activities,independent of their known proapoptotic or cell cycle arrest actions on malignant cells. low concentrations of hdaci's are effective in reducing inflammation and autoimmune response in humans with juvenile idiopathic arthritis and animal models of inflammatory bowel disease and arthritis. the project was undertaking by qilu hospital of shandong university in china. in order to report the efficacy and safety of the low dose chidamide in the management of refractory itp.

the investigators are undertaking a prospective, open, multicentre trial of 30 refractory itp adult patients from 5 medical centers in china. 1/2 of the participants are randomly selected to receive chidamide in 2.5 mg po tiw, every four weeks for one cycle and it will be given three cycles. the other part will receive chidamide in 5 mg po tiw, every four weeks for one cycle and it will be given three cycles. the treatment was discontinued after 3 months without blood index reaction. platelet count, bleeding and other symptoms were evaluated before and after treatment. adverse events are also recorded throughout the study. in order to report the efficacy and safety of the low dose chidamide in the management of refractory itp.

Eligibility criteria:
inclusion criteria: * refractory itp patients need of treatment(s) to minimize the risk of clinically significant bleeding primary itp confirmed by excluding other supervened causes of thrombocytopenia exclusion criteria: * pregnancy hypertension cardiovascular disease diabetes liver and kidney function impairment hcv, hiv, hbsag seropositive status patients with systemic lupus erythematosus and/or antiphospholipid syndrome

Keywords: itp chidamide
correlation between selected haematological and doppler ultrasonic parameters in peripheral arterial diseased patients

Conditions: Peripheral Arterial Disease

Summary: forty patients of both sexes, aged between 50 and 60 years, were chosen from an outpatient vascular clinic in the el sahel education hospital. patients have been examined and referred to by a vascular specialist.

the participants were divided randomly into two groups of equal numbers. the study group got low-frequency tens (4 hz frequency, pulse duration 200 μs) which was administered through surface electrodes for 45 min per session, supramaximal stimulation for t12, l1, and l2 sympathetic ganglions that innervate the lower extremity for 45 min per session, three times per week and for 12 weeks. control group that received placebo stimulation as provided by the same tens device but with a zero volt after 10 s of stimulation.

Eligibility criteria:
inclusion criteria: 1. unilateral leriche-fontaine stage-ii pad 2. both sexes 3. aged 50 to 60 years 4. outpatients 5. clinically stable 6. sedentary 7. not participating in any physical activity last 3 months exclusion criteria: 1. walking disorders related to orthopedic or neuromuscular disease 2. renal insufficiency requiring dialysis (renal diseases) 3. known and documented myopathy 4. progressive cancer 5. associated progressive disease causing a deterioration in general health 6. participation in another research protocol 7. skin disorder making it impossible to use tens 8. absolute contraindication to physical activity 9. presence of a pacemaker/defibrillator
haic plus lenvatinib and pd-1 antibody versus haic plus lenvatinib for advanced hcc

Conditions: Hepatocellular Carcinoma

Summary: the purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin plus lenvatinib and programmed cell death protein-1 antibody compared with lenvtinib alone in patients with hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin plus lenvatinib for advanced hepatocellular carcinoma (hcc)

hepatic arterial infusion chemotherapy (haic) of oxaliplatin, 5-fluorouracil and leucovorin was effective and safe for hepatocellular carcinoma. lenvatinib was non-inferior to sorafenib in overall survival in untreated advanced hepatocellular carcinoma, and programmed cell death protein-1 (pd-1) antibody was effective and tolerable in patients with advanced hepatocellular carcinoma. no study has compared haic plus lenvatinib and pd-1 antibody with haic plus lenvatinib. thus, the investigators carried out this prospective randomized control study to find out it.

Eligibility criteria:
inclusion criteria: * the diagnosis of hcc was based on the diagnostic criteria for hcc used by the european association for the study of the liver (easl) * patients must have at least one tumor lesion that can be accurately measured according to easl criteria. * barcelona clinic liver cancer-stage c * eastern cooperative oncology group performance status of 0 to 2 * with no previous treatment * no cirrhosis or cirrhotic status of child-pugh class a only * not amendable to surgical resection ,local ablative therapy and any other cured treatment. * the following laboratory parameters: hemoglobin ≥ 8.5 g/dl total bilirubin ≤ 30mmol/l serum albumin ≥ 30 g/l asl and ast ≤ 5 x upper limit of normal serum creatinine ≤ 1.5 x upper limit of normal inr ≤ 1.5 or pt/aptt within normal limits absolute neutrophil count (anc) \>1,500/mm3 • ability to understand the protocol and to agree to and sign a written informed consent document exclusion criteria: * evidence of hepatic decompensation including ascites, gastrointestinal bleeding or hepatic encephalopathy * known history of hiv * history of organ allograft * known or suspected allergy to the investigational agents or any agent given in association with this trial. * cardiac ventricular arrhythmias requiring anti-arrhythmic therapy * evidence of bleeding diathesis. * patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry. * known central nervous system tumors including metastatic brain disease

Keywords: hepatocellular carcinoma lenvatinib pd-1 antibody oxaliplatin, 5-fluorouracil and leucovorin hepatic arterial infusion chemotherapy
efficacy of rituximab combined with cyclosporine in the treatment of idiopathic membranous nephropathy

Conditions: Idiopathic Membranous Nephropathy

Summary: idiopathic membranous nephropathy (imn) is one of the common types of primary glomerular diseases and the most common cause of nephrotic syndrome in adults. poticelli regimen is the classic treatment, but cyclophosphamide has many toxic side effects. the period of glucocorticoid therapy is relatively long, and the adverse reactions caused by glucocorticoid therapy cannot be ignored. for patients who are unwilling to receive glucocorticoids and cyclophosphanide or who have treatment contraindications, cyclosporine can be used, mainly cyclosporine and tacrolimus, with the rapid overall effect but a high short-term relapse rate. in recent years, rituximab therapy has become a first-line treatment, with a high remission rate, and few side effects, but expensive. in terms of efficacy alone, the above regimen did not exceed poticelli regimen. however, the toxic side effects of rituximab, cyclosporine may be lower than that of poticelli regimen. based on the preliminary experiment, this study explored a new treatment plan: low-dose rituximab combined with cyclosporine in the treatment of imn, the efficacy is not inferior to poticelli regimen, but the side effects are significantly reduced. the result will provide a good choice for imn patients.


Eligibility criteria:
inclusion criteria: 1. age 18-70 years; serum albumin level \<30 g/l; 2. estimated glomerular filtration rate (egfr according to the ckd-epi formula) ≥60 ml/min per 1.73 m2; 3. patients with a moderate risk of imn and decline \<50% in proteinuria despite blockade of the renin-angiotensin system 3 months before randomization; 4. patients at high risk or very high risk of imn. exclusion criteria: 1. secondary causes of mn; 2. being pregnant or breastfeeding; 3. uncontrollable active infectious disease; 4. immunosuppressive treatment in the preceding 3 months.
survey of smokers treated in the emergency department (ed) on ownership and usage of cell phones

Conditions: Smoking

Summary: to study ownership and use of cell phones in low-income smokers. this may help us better understand the impact of cell phone ownership plans on low income smokers' access to quitlines. use of quitlines may be impeded by limited access to landline phones and limited airtime minutes on cell phones.


Eligibility criteria:
inclusion criteria: * age 18 or over * speak and understand english * willing and able to give informed consent * have smoked more than 100 cigarettes lifetime * are currently a daily or some day smoker exclusion criteria: * too ill or unable to consent * not interested in participation * actively psychotic or mentally ill and unable to give consent * in police custody * resides in an extended care facility.

Keywords: smoking cellular phones low income population
safety and efficacy study of epi-743 in children with leigh syndrome

Conditions: Leigh Syndrome

Summary: the purpose of this study is to evaluate the effects of epi-743 in children with leigh syndrome on disease severity, neuromuscular function, respiratory function, disease morbidity and mortality and disease associated biomarkers.

the purpose of this study is to evaluate the effects of epi-743 in patient with leigh syndrome on disease severity, neuromuscular function, respiratory function, disease morbidity and mortality and biomarkers associated with the disease. this study is a six month prospective randomized double-blind, placebo-controlled trial with a six month extension phase of two dose levels of epi743. the planned enrollment is for approximately 30 children with genetically confirmed leigh syndrome. after 6 months of treatment, those children that were randomized to the placebo treatment arm will be re-randomized to one of the 2 active treatment arms.

Eligibility criteria:
inclusion criteria: * clinical and mri diagnosis of leigh syndrome * moderate disease severity based on npmds score * age under 18 years * documented evidence of disease progression within 12 month of enrollment * availability of mri that confirms necrotizing encephalopathy * patient or guardian able to consent and comply with protocol requirements * abstention from coenzyme q10, vitamins c \& e, lipoic acid and idebenone exclusion criteria: * allergy to epi-743, vitamin e or sesame oil * history of bleeding abnormalities or abnormal pt/ptt * diagnosis of concurrent inborn error of metabolism * previous tracheostomy * ventilator dependent or use of noninvasive ventilatory support w/in 1 month of enrollment * lfts greater than 2 times uln * renal insufficiency * end stage cardiac failure * fat malabsorption syndrome * use of anticoagulant medications * abstention from botox for 6 months prior to enrollment and for duration of study

Keywords: epi743 leigh syndrome respiratory chain disease mitochondrial disorders
implementation and effectiveness of the bjc-pink and pearl project on lung cancer screening

Conditions: Lung Cancer; Cancer of the Lung

Summary: the investigators proposal is ripe for executing as the investigators seek to leverage this "natural experiment" initiated by the bjc health system to evaluate the effectiveness of the pink \& pearl campaign as an implementation strategy to promote lung cancer screening (lcs) uptake among lcs-eligible women undergoing mammography at bjc west county. this evaluation is grounded in the integrated screening action model that depicts individual- and environmental-level influences on the screening behavior process. using an explanatory sequential mixed methods design, which combines both quantitative and qualitative approaches, the research questions and specific aims for this proposal are to: a) evaluate the baseline prevalence of lcs among lcs-eligible women; b) assess whether the pink \& pearl campaign increases referrals and uptake/ completion of lcs among lcs-eligible women undergoing screening mammography; and c) evaluate individual and environmental factors influencing lcs uptake, and implementation outcomes of the campaign. these implementation outcomes will help identify whether the campaign was put in place successfully or not. this proposal will inform strategies for integrating cancer screening programs to improve poorly performing programs like lcs.


Eligibility criteria:
inclusion criteria for participants: * undergoing screening mammography * between the ages of 50-80 years (inclusive) * reporting a 20 pack-year equivalent of either current smoking history or have quit in the past 15 years * can speak and understand english * ability to understand willingness to provide informed consent. exclusion criteria for participants: * diagnosed with a serious health problem that will likely limit life expectancy (such as previous history of lung cancer, symptoms of lung cancer such as hemoptysis or unexplained weight loss of more than 6.8 kg (15 lb) in the previous year) * subjects with symptoms of lung cancer should get a diagnostic ct scan * unable or unwilling to get treatment if lung cancer is found eligibility criteria for providers: * older than 20 years of age

Keywords: lung cancer screening (lcs) pink and pearl campaign breast cancer screening (bcs) low-dose computed tomography (ldct) smoking history health disparities screening behavior feasibility acceptability appropriateness
using tablets for upper extremity rehabilitation post acquired brain injury

Conditions: Brain Injury; Stroke

Summary: the purpose of the study is to test the effectiveness of training using novel tablet applications for hand function, compared to traditional hand exercises. in addition, we aim to examine brain plasticity following treatment with the new tablet applications. we hypothesize that training with a tablet would prove to be more effective than traditional exercises. we expect to observe neuroplastic changes in the brain in patients who practiced finger movements using the tablet.


Eligibility criteria:
inclusion criteria: * at least one week post brain injury or stroke * partial ability to open and close their hand (fingers) * full function of the hands prior to the injury or event * intact or corrected vision * cognitively intact or mild impairment exclusion criteria: * other neurological conditions besides the brain injury or stroke * orthopedic conditions of the upper extremity

Keywords: hand rehabilitation stroke brain-injury tablet
effects of non-surgical periodontal therapy on severe periodontitis and hyperlipidemia

Conditions: Periodontitis Chronic Generalized Severe; Hyperlipidemia; Gingival Crevicular Fluid; Serum; Biomarkers; Non-surgical Periodontal Therapy

Summary: this study was a single-center, non-randomized, parallel-group design clinical trial, and each group was assigned a 1:1 ratio with or without hyperlipidemia. both groups underwent periodontal non-surgical treatment, and blood and gingival crevicular fluid were collected before surgery, 1 month and 3 months after surgery for the detection of mcp-1, il-8, oxldl, tnf-α, tg, ldl-c, hdl-c.

this study was a single-center, non-randomized, parallel-group design clinical trial, and each group was assigned a 1:1 ratio with or without hyperlipidemia. both groups underwent periodontal non-surgical treatment, and blood and gingival crevicular fluid were collected before surgery, 1 month and 3 months after surgery for the detection of mcp-1, il-8, oxldl, tnf-α, tg, ldl-c, hdl-c.mcp-1, il-8, oxldl, tnf-α will be tested for concentration using elisa.

Eligibility criteria:
inclusion criteria: * subjects had to meet at least one of the following criteria for the diagnosis of hyperlipidemia: triglyceride (trg) levels \>2.26 mmol/l; high density lipoprotein cholesterol (hdl-c) levels \ 4.14 mmol/l * patients with severe periodontitis (stage iii/iv) with probing depth (pd) ≥ 6 mm at at least six sites, at least two multi-rooted or two single-rooted teeth in at least one quadrant, and extended bone loss on imaging to the middle or top third of the root. periodontitis results in the loss of less than or equal to four teeth. exclusion criteria: * systemic illnesses * pregnancy or lactation * systemic antibiotics taken within the previous 6 months * use of cholesterol reduction medication during the past 6 months * subgingival scaling and root planing or surgical periodontal therapy in the last year * chewing smokeless tobacco, smoking pipes or cigars 1 or more times per week, or smoking more than 20 cigarettes per week (1 pack per week) in the past 6 months

Keywords: severe periodontitis hyperlipidemia gingival crevicular fluid serum biomarkers non-surgical periodontal therapy
effectiveness of nitrous oxide in the ed

Conditions: Lacerations; Abscess

Summary: this will be a randomized control trial. all patients for whom an emergency provider determines that abscess drainage or laceration repair are necessary will be considered for enrollment. the provider must be willing to participate in the study and be certified to use nitrous oxide. the investigators providers completed a training course to be certified to use nitrous oxide. the patient must be age 18 or greater, consent to participate in the study, and be able to complete a satisfaction survey. if the patient states there is a possibility of pregnancy, the investigators will regress to our standard of care and perform a urine pregnancy test. patients with a first trimester pregnancy will be excluded. patients who agree to enroll in the study will be randomized to nitrous oxide versus oxygen (to be administered through the same system), and will complete a survey after the procedure, as will the provider. there will be a separate block randomization for each procedure. providers may select other agents of choice for analgesia/sedation, such as local anesthesia, and pain medications, based on their clinical judgment. if the patient appears to have inadequate analgesia during the procedure, the provider can elect to treat as is typically done (pain medications or local anesthetics) at their discretion. the survey will ask patients to give a self-reported pain score before and during their procedure (both to be completed after the procedure). it will also ask the patient/guardian and provider for a satisfaction level with the analgesia during the procedure. in addition, side effects and procedure start and stop time will also be documented. in addition to the survey, the investigators will document clinical characteristics including diagnosis, size of laceration or abscess, additional medications required and dosages, comorbidities, age, and gender. other data that will be gathered will include which adjunctive analgesics/anesthetics were used.


Eligibility criteria:
inclusion criteria: patients with: * a laceration or an abscess requiring primary repair or incision and drainage respectively, per the treating provider exclusion criteria: * age \< 18 years * first trimester pregnancy * inability to obtain written informed consent from subject or surrogate